Armour: Relaxin in CRPC

Armour targets relaxin in prostate cancer; may complement anti-androgen drugs

Armour Therapeutics Inc.'s relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway could delay the time to when the disease becomes hormone refractory.

Prostate cancer therapies have predominantly targeted the androgen pathway, as aberrant androgen production drives tumor growth and metastases. These treatments include older therapies such as androgen hormone antagonists and newer compounds such as Zytiga abiraterone from Johnson & Johnson, which

Read the full 845 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE